J&J Says Its COVID-19 Vaccine Effective Against Delta Variant

J&J Covid-19 vaccine, Delta Variant: It also provides durable protection against the infection, the company said.

<div class="paragraphs"><p>J&amp;J COVID-19 Vaccine: The data showed that the durability of the immune response lasted through at least eight months.</p></div>

The Johnson & Johnson COVID-19 vaccine is effective against the highly contagious Delta variant and other emerging strains, and also provided durable protection against the infection more broadly, the company said.

The US-based company said in a statement that its single-shot COVID-19 vaccine "generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants."

The Delta variant was first detected in India and has now spread to over 90 countries worldwide.

The data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date.
Johnson & Johnson

The two preprint study summaries have been submitted to bioRxiv.


“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time," Mathai Mammen, head of research & development at J&J's drugs business, said in the statement.

The Findings of the Study

The findings disclosed were from two studies. The company has submitted data as a preprint to bioRxiv ahead of peer review.

Johnson & Johnson evaluated the blood samples of eight participants in its late-stage clinical trial of the vaccine to assess neutralising antibodies against the delta variant.

These data showed that the vaccine elicited neutralizing antibody activity against the Delta variant at an even higher level than what was recently observed for the Beta (B.1.351) variant in South Africa where high efficacy against severe/critical disease was demonstrated, the company said.

The COVID-19 vaccine was also 85 percent effective against severe/critical disease and demonstrated protection against hospitalization and death.

Data submitted by Dan Barouch of Beth Israel Deaconess Medical Center showed that humoral and cellular immune responses generated by the vaccine lasted through at least eight months.

"Data showed that T-cell responses – including CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined," the company said.

(Subscribe to FIT on Telegram)

Stay Up On Your Health

Subscribe To Our Daily Newsletter Now.

Join over 120,000 subscribers!